Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti–Tumor Necrosis Factor Therapy for Crohn’s Disease: A Meta-analysis of Placebo-controlled Trials-Reference-Cited by-同舟云学术

Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti–Tumor Necrosis Factor Therapy for Crohn’s Disease: A Meta-analysis of Placebo-controlled Trials

Published:2015-12 Issue:13 Volume:13 Page:2233-2240.e2
ISSN:1542-3565
Container-title:Clinical Gastroenterology and Hepatology
language:en
Short-container-title:Clinical Gastroenterology and Hepatology

Author:

Jones Jennifer L.,Kaplan Gilaad G.,Peyrin-Biroulet Laurent,Baidoo Leonard,Devlin Shane,Melmed Gil Y.,Tanyingoh Divine,Raffals Laura,Irving Peter,Kozuch Patricia,Sparrow Miles,Velayos Fernando,Bressler Brian,Cheifetz Adam,Colombel Jean-Frederic,Siegel Corey A.

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference38 articles.

1. Certolizumab pegol for the treatment of Crohn's disease;Sandborn;N Engl J Med,2007

2. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial;Sandborn;Gut,2007

3. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial;Sandborn;Ann Intern Med,2007

4. Infliximab maintenance therapy for fistulizing Crohn's disease;Sands;N Engl J Med,2004

5. Maintenance therapy with certolizumab pegol for Crohn's disease;Schreiber;N Engl J Med,2007

Cited by 107 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) (Version 4.1) – living guideline;Zeitschrift für Gastroenterologie;2024-08

2. Controversies in the management of anti-TNF therapy in patients with Crohn’s disease: a Delphi consensus;BMJ Open Gastroenterology;2024-01

3. Pediatric IBD Patients Treated With Infliximab and Proactive Drug Monitoring Benefit From Early Concomitant Immunomodulatory Therapy: A Retrospective Analysis of a 10-Year Real-Life Cohort;Inflammatory Bowel Diseases;2023-11-27

4. To Combine or Not to Combine: Do We Need Concomitant Immunomodulators When Using Non-TNF-Targeting Biologics?;Clinical Gastroenterology and Hepatology;2023-10

5. Persistence Among Patients with Crohn Disease Previously Treated with an Anti-tumor Necrosis Factor Inhibitor and Switching or Cycling to Another Biologic Agent;Clinical Therapeutics;2023-08